APSR2026-530

Yes
Regular
Submitted
Oral Presentation
AO01-004
 
 
 
Format: PPTX Only
 
Format: PDF Only
09. Asthma
15

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Koichi Jingo * Juntendo University Faculty of Medicine and Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Hiroki Kabata - Keio University School of Medicine Department of Pulmonary Medicine Tokyo Japan
Sahoko Imoto - Teikyo University Hospital Respiratory Medicine Tokyo Japan
Taichi Mochizuki - International University of Health and Welfare (IUHW) Mita Hospital Respiratory Diseases Center Tokyo Japan
Yasuhiro Gon - Nihon University School of Medicine Department of Internal Medicine, Division of Respiratory Medicine Tokyo Japan
Takanori Numata - The Jikei University School of Medicine Department of Internal Medicine, Division of Respiratory Diseases Tokyo Japan
Mayoko Tsuji - Tokyo Women’s Medical University Department of Respiratory Medicine Tokyo Japan
Akihiko Tanaka - SHOWA Medical University Division of Respiratory Medicine and Allergology Tokyo Japan
Masayuki Hojo - Center Hospital of the National Center for Global Health and Medicine Respiratory Medicine Tokyo Japan
Osamu Nagashima - Juntendo University Faculty of Medicine and Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Kei Matsuno - Juntendo University Faculty of Medicine and Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Tomohito Takeshige - Juntendo University Faculty of Medicine and Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Mitsuhiro Fujii - Juntendo University Faculty of Medicine and Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Kazuhisa Takahashi - Juntendo University Faculty of Medicine and Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Norihiro Harada - Juntendo University Faculty of Medicine and Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Presenting Author Details
Koichi
Jingo
k.jingo.lb@juntendo.ac.jp
+819095970677
31-40
Japan
Original Research
Biomarkers and Competing-Risk Analysis of Tezepelumab Response in Real-world Severe Asthma: TOkyo Asthma STudy for Tezepelumab (TOAST2)
Maximum 25 words
Abstract Content

Tezepelumab was approved for severe asthma in Japan in 2022, but real-world effectiveness data remain limited. We aimed to identify biomarkers predicting response and to evaluate how discontinuation due to adverse events or other reasons influences treatment assessment.

We prospectively analyzed 65 patients with severe asthma who initiated tezepelumab at 13 institutions (December 2023–October 2024). A 3-WAY responder met all: (1) ACQ-6 ≤ 0.75 or ΔACQ-6 ≤ -0.5, (2) no exacerbations, and (3) no maintenance oral corticosteroids. A 4-WAY responder was a 3-WAY responder additionally meeting %FEV1 ≥ 80% or ΔFEV1 ≥ 100 mL. P < 0.05 was considered significant. 

McNemar exact tests showed significant changes in 3-WAY response rates at weeks 24 and 52 versus baseline. Week-52 response was more frequent among those achieving 3-WAY at week 24 (risk difference 46.67 percentage points; 95% CI 16.33–66.74; risk ratio 2.40; 95% CI 1.26–4.57). ANCOVA showed a greater week-24 change in FEV1 in patients with baseline FeNO ≥ 50 ppb. Nineteen patients discontinued during follow-up. Cox models treated discontinuation as censoring and Fine–Gray models treated it as a competing event; Wald Z tests (normal approximation; H0: mean = 0) were applied to baseline values and changes. Older age, smoking history, and baseline eosinophils ≥ 300/μL were significant in both models. Baseline eosinophils were also associated with 4-WAY response; baseline ACT was associated with both 3-WAY and 4-WAY response, whereas ACQ-6 was associated with 3-WAY only. Findings were directionally consistent across alternative competing-risk definitions for discontinuation. 

In severe asthma, tezepelumab effectiveness appeared to be associated with baseline eosinophil counts. Older age and a history of smoking may be associated with higher instantaneous and cumulative response. Lung function improvement may also be greater in patients with higher baseline FeNO.

No
No
 
JPG or JPEG or PNG format ONLY
Tezepelumab, Biomarkers, Eosinophils
maximum 3 keywords and no abbreviations, separated by commas
 
292